Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ASTNASDAQ:ATNFWOTCMKTS:DDXSNASDAQ:KLDO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsATNFW180 Life Sciences$0.01-4.8%$0.01$0.00▼$0.04N/AN/A97,681 shs9,714 shsDDXSDiadexus$0.00$0.01▼$5.40$53KN/A15,481 shs30 shsKLDOKaleido Biosciences$0.00$0.00▼$0.07$4K-0.069,185 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%ATNFW180 Life Sciences-4.76%-8.05%-1.23%+5.26%-12.09%DDXSDiadexus0.00%0.00%0.00%0.00%0.00%KLDOKaleido Biosciences0.00%0.00%-50.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ADDXSDiadexusN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASTAsterias Biotherapeutics 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ADDXSDiadexus 0.00N/AN/AN/AKLDOKaleido Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ADDXSDiadexusN/AN/AN/AN/AN/AN/AKLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ADDXSDiadexusN/AN/A0.00N/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ADDXSDiadexusN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASTAsterias BiotherapeuticsN/AATNFW180 Life SciencesN/ADDXSDiadexusN/AKLDOKaleido Biosciences81.56%Insider OwnershipCompanyInsider OwnershipASTAsterias BiotherapeuticsN/AATNFW180 Life SciencesN/ADDXSDiadexusN/AKLDOKaleido Biosciences9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableDDXSDiadexusN/A4.10 millionN/ANot OptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionableAST, DDXS, KLDO, and ATNFW HeadlinesRecent News About These CompaniesKaleido Life Introduces the Third Way to Fund Your Future: Cash. Credit. Kaleido.May 19, 2025 | gritdaily.comGKaleido Biosciences Inc (KLDO)April 10, 2025 | uk.investing.comCelebration As NSW’s First LGBTQIA+ Dedicated Health Service Kaleido Opens Its DoorsApril 9, 2025 | starobserver.com.auSKaleido Intelligence: Transport & Logistics Cellular Data to Surpass 2 Exabytes by 2030April 3, 2025 | thefastmode.comTKaleido, Mobilesquared Announce Merger to Revolutionize Mobile Market IntelligenceJanuary 19, 2025 | thefastmode.comTSyniverse Named Leader in Mobile Roaming by Kaleido Intelligence for Fourth Straight YearDecember 11, 2024 | finance.yahoo.comBICS, Cellusys, Comfone, Mobileum, Syniverse, Telefónica Global Solutions & TOMIA MACH Named Champion Roaming Vendors by Kaleido IntelligenceNovember 25, 2024 | markets.businessinsider.comNew PocketBook Color Note With 10.3-inch E Ink Kaleido 3 Mobius Display LaunchedNovember 1, 2024 | goodereader.comGViCentra wins CE mark for Kaleido insulin pumpOctober 21, 2024 | drugdeliverybusiness.comDKaleido Biosciences (OTC:KLDO) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comKaleido announces the appointment of RBC Investor Services as the new custodian of its scholarship plansOctober 1, 2024 | ca.finance.yahoo.comNew Readmoo mooInk Nana e-Reader With 7-inch Kaleido 3 Display LaunchedSeptember 29, 2024 | goodereader.comGiReader Smart 5C e-Note With 10.3-inch Kaleido 3 to Launch on Sept. 23September 14, 2024 | goodereader.comGOnyx Boox T10C e-Note With Kaleido 3 Display LaunchedSeptember 7, 2024 | goodereader.comGMoaan Pantone 7 e-Reader with Kaleido 3 E-Paper Display Now AvailableAugust 19, 2024 | goodereader.comGKaleidoscope Digital Media Systems, DBA of Kaleidoscope Venture Capital Inc., Announces the Creation of Kaleidoscope Internet...August 17, 2024 | br.advfn.comLoFone, the Latest Anti-Smartphone to Feature E Ink Kaleido 3 DisplayAugust 11, 2024 | goodereader.comGPocketBook Verse Pro Color With 6-inch Kaleido 3 Display LaunchedJuly 30, 2024 | goodereader.comGMoan Pantone 6 e-Reader With Kaleido 3 Display LaunchedMay 22, 2024 | goodereader.comGReadmoo Mooink Pro 2C Review 13.3 E INK Kaleido 3 E-note ReviewMay 18, 2024 | goodereader.comGMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI Spending3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeWhy Nebius Group Is One of the Top AI Stocks to WatchBy Thomas Hughes | June 17, 2025View Why Nebius Group Is One of the Top AI Stocks to WatchAST, DDXS, KLDO, and ATNFW Company DescriptionsAsterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.180 Life Sciences NASDAQ:ATNFW$0.0080 0.00 (-4.76%) As of 06/27/2025 03:55 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Diadexus OTCMKTS:DDXSDiadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.Kaleido Biosciences NASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
